Worth being precise before going further, since the brand names get used almost interchangeably online. Ozempic and Wegovy are the same drug, semaglutide, made by Novo Nordisk; Ozempic is licensed in the UK for type 2 diabetes, Wegovy for weight management, and the two aren't meaningfully different pharmacologically. Mounjaro and Zepbound are likewise the same drug, tirzepatide, made by Eli Lilly, split the same way between a diabetes licence (Mounjaro) and a weight management one (Zepbound, not currently marketed in the UK under that name). Mounjaro is the one most UK readers will actually encounter, available both on the NHS in specific circumstances and widely through private prescription.

Retatrutide is a different, newer compound again, a triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly, still in Phase 3 trials and not licensed anywhere. All of these sit in the same broad drug class, while the substantial weight loss they produce raises a shared question around hair shedding.

Rather than relying on secondary summaries, we pulled the adverse event data directly from the trial record.

That dose-response pattern, more hair loss at the dose producing more weight loss, is consistent with rapid weight loss itself being a driver: it's a recognised trigger for telogen effluvium (TE), a temporary, diffuse shedding pattern where a disproportionate number of follicles are pushed into the resting phase at once. The mechanism and typical timeline are covered in full in our articles on telogen effluvium vs androgenetic alopecia and nutritional deficiencies and hair loss, rather than repeated here.

Given how widely Mounjaro is now prescribed in the UK, its trial data is arguably more directly relevant to most readers here than semaglutide's.

Tirzepatide's product information reflects this indication split directly. Alopecia appears in the product labelling for tirzepatide's weight-management indication, drawing on the SURMOUNT-1 data above, but was absent from the earlier labelling covering type 2 diabetes alone, where the trial evidence behind the medicine didn't involve the same scale of weight loss. That pattern is consistent with weight loss playing an important role in the observed alopecia signal, although it doesn't establish that weight loss is the only mechanism involved.

Two things are worth holding at once here. First, "not prominently reported" isn't the same as "doesn't happen": hair shedding is often under-captured in trial adverse-event reporting unless participants are specifically asked about it, since many people don't think to report a cosmetic change as a medical adverse event. Second, retatrutide produces substantial and rapid weight loss, which provides a plausible basis for telogen effluvium risk on the same general grounds as other major weight-loss interventions. But without retatrutide-specific hair-loss data, we can't establish whether that risk is lower, similar to, or greater than with semaglutide or tirzepatide; the tirzepatide data above, where alopecia didn't climb further between the 5mg and 15mg doses, is a reminder that a simple "more weight loss means more shedding" relationship doesn't hold cleanly even within a single drug's own trial, let alone across different trials, populations, and protocols.

Some sources online cite a specific figure, hair loss occurring in "10 to 15% of retatrutide users," attributed to clinical trial data. We couldn't verify this against the actual trial record, and it doesn't appear in the published Phase 2 results. It's worth treating that specific number with the same scepticism we've applied to other precisely-stated but uncited claims elsewhere on this site.

As with telogen effluvium from any cause, the appetite suppression that drives GLP-1-related weight loss also makes it easier to fall short on protein and key micronutrients, which can compound the shed on top of the weight-loss trigger itself. Monitoring ferritin, B12, and vitamin D during treatment, alongside adequate protein intake as weight drops, is a practical, evidence-supported step, covered in more depth in our nutritional deficiencies article. Acute TE also generally resolves on its own once weight stabilises, the same recovery pattern covered in our article on AHK-Cu and telogen effluvium.

Worth being direct about where a topical active fits into this specifically: nothing applied to the scalp addresses the actual trigger, which is the rate and extent of weight loss and whatever nutritional gaps accompany it. AHK-Cu and 2dDR aren't tested in a GLP-1-related shedding context specifically, and there's no reason to expect either would speed up recovery beyond what happens naturally once weight stabilises. There's also no reason to expect either would interfere with that recovery. If you're using a topical during this period, it's reasonable to think of it as a general follicle-support measure alongside addressing the actual cause, not a way to prevent or shorten GLP-1-related shedding specifically.

This article is provided for educational purposes and does not constitute medical advice. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition. GLP-1 receptor agonists are prescription medicines; any questions about their use, including hair-related side effects, should be directed to your prescriber. Retatrutide is an investigational drug not currently approved for use outside clinical trials.

AmpleLab.